A previous study showed that anti-androgen therapy has a better effect on tumorigenesis in the ERG subtypes of prostate cancer [23], and we expect a similar effectiveness from anti-androgen therapy in ETV4-fusion-positive prostate cancer, based on its unique features of cellular signaling pathways. The gene discussed is ETV4; the disease is prostate carcinoma.